Footnotes

CHAPTER 1 - INTRODUCTION

[1]        Community Affairs References Committee, Consumer Access to Pharmaceutical Benefits Report, 26 August 2010, p. 2.

[2]        Community Affairs References Committee, Report on matters referred to the Community Affairs References Committee in the 42nd Parliament, 30 September 2010, p. 1. 

[3]        Department of Health and Ageing (DoHA), What is the PBS?, available: http://www.pbs.gov.au/html/consumer/pbs/about (accessed 2 May 2010). 

[4]        DoHA, New PBS Safety Net thresholds, available: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbs-safetynet-changes (accessed 6 May 2010).

[5]        DoHA, Submission 27, p. 5. 

[6]        DoHA, Submission 27, p. 5. 

[7]        DoHA, Submission 27, p. 5. 

[8]        DoHA, PBAC Membership, available: http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-listing-pbacmembership.htm (accessed 6 May 2010). 

[9]        DoHA, Pharmaceutical Benefits Advisory Committee, available: http://www.health.gov.au/internet/main/publishing.nsf/Content/health-pbs-general-listing-committee3.htm#pbac (accessed 29 July 2010). 

[10]      DoHA, Submission 27, p. 10. 

[11]      DoHA, Submission 27, p. 10. 

[12]      DoHA, Submission 27, p. 10. 

[13]      Mr David Learmonth, Deputy Secretary, DoHA, Committee Hansard, 7 May 2010, pp 92-93. 

[14]      DoHA, Submission 27, p. 10. 

[15]      DoHA, Submission 27, p. 9. 

[16]      DoHA, Submission 27, p. 11. 

[17]      Prior to 2007, the therapeutic group pricing policy had been an administrative measure; DoHA, Submission 27, p. 11

[18]      DoHA, Submission 27, p. 11. 

[19]      DoHA, Submission 27, p. 12. 

[20]      DoHA, Submission 27, p. 12. 

[21]      The Hon Nicola Roxon MP, Minister for Health and Ageing, 'MYEFO points to rising health costs', media release, 2 November 2009.

[22]      DoHA, Submission 27, p. 12. 

[23]      Mid-Year Economic Outlook 2009-10, available: http://www.budget.gov.au/2009-10/content/myefo/download/MYEFO_2009-10.pdf (accessed 7 April 2010), p. 197. 

[24]      DoHA, Submission 27, p. 12. 

[25]      National Health (Pharmaceutical Benefits – Therapeutic Groups) Determination 2010, Parts 8, 9 & 10. 

[26]      DoHA, Submission 27, p. 15. 

[27]      DoHA, Submission 27, p. 15. 

[28]      DoHA, Submission 27, p. 16. 

[29]      DoHA, Submission 27, p. 16. 

[30]      DoHA, Submission 27, p. 20. 

[31]      Productivity Commission, Annual Review of Regulatory Burdens on Business: Manufacturing and Distributive Trades, 16 September 2008, p. 80.

[32]      DoHA, Submission 27, p. 20. 

[33]      Commonwealth Government & Medicines Australia, Memorandum of Understanding, 6 May 2010, p. 4. 

[34]       In paragraphs 16 and 17 of the MOU, the government has undertaken not to create any new therapeutic groups, except in certain prescribed circumstances, and to provide reasonable notice of its intention to create new therapeutic groups; Commonwealth Government & Medicines Australia, Memorandum of Understanding, 6 May 2010, p. 4.

[35]      Commonwealth Government & Medicines Australia, Memorandum of Understanding, 6 May 2010, p. 6. 

[36]      Commonwealth Government & Medicines Australia, Memorandum of Understanding, 6 May 2010, p. 6. 

[37]      Commonwealth Government & Medicines Australia, Memorandum of Understanding, 6 May 2010, p. 6. 

CHAPTER 2 - CONSULTATION AND TRANSPARENCY

[1]        Department of Health and Ageing (DoHA), Submission 27, pp 17-18. 

[2]        Mr David Learmonth, Deputy Secretary, DoHA, Committee Hansard, 7 May 2010, p. 93. 

[3]        Mr Andrew Stuart, First Assistant Secretary, Pharmaceutical Benefits Division, DoHA, Committee Hansard, 7 May 2010, p. 94. 

[4]        Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 7 May 2010, p. 6.

[5]        Pfizer Australia, Submission 33, p. 19.

[6]        sanofi-aventis Australia Pty Ltd, Submission 23, p. 8. 

[7]        sanofi-aventis Australia Pty Ltd, Submission 23, pp 8 & 9. 

[8]        Pfizer Australia, Submission 33, p. 23. 

[9]        Medicines Australia, Answers to questions on notice, 7 May 2010 (received 31 May 2010).

[10]      Medicines Australia, Answers to questions on notice, 7 May 2010 (received 31 May 2010).

[11]      Commonwealth Government & Medicines Australia, Memorandum of Understanding, 6 May 2010, p. 4.

[12]      See for example Epilepsy Council of Australia & Epilepsy Australia, Submission 15, p. 1 & Mr David Crosbie, Chief Executive Officer, Mental Health Council of Australia (MHCA), Committee Hansard, 7 May 2010, p. 29. 

[13]      See Associate Professor Stephen Oakley, Committee Hansard, 7 May 2010, p. 67 & Dr Charles Inderjeeth, Member, Australian and New Zealand Society for Geriatric Medicine, Committee Hansard, 7 May 2010, pp 68 & 69. 

[14]      Epilepsy Council of Australia & Epilepsy Australia, Submission 15, p. 1. 

[15]      Mr David Crosbie, Chief Executive Officer, MHCA, Committee Hansard, 7 May 2010, p. 29. 

[16]      Australian and New Zealand Bone and Mineral Society (ANZBMS), Submission 9, pp 2-3. 

[17]      Consumers Health Forum (CHF), Submission 20, p. 3.

[18]      MHCA, Submission 25, p. 3.

[19]      Mr David Crosbie, Chief Executive Officer, MHCA, Committee Hansard, 7 May 2010, p. 29. 

[20]      Ms Sue Aiesi, Policy, Communications and Research Manager, Carers Australia, Committee Hansard, 7 May 2010, p. 30. 

[21]      Ms Carol Bennett, Executive Director, CHF, Committee Hansard, 7 May 2010, p. 60. 

[22]      See CHF, Answers to questions on notice, 7 May 2010 (received 19 May 2010); Arthritis Australia, Answers to questions on notice, 7 May 2010 (received 20 May 2010) & MHCA, Answers to questions on notice, 7 May 2010 (received 25 May 2010).

[23]      Ms Carol Bennett, Executive Director, CHF, Committee Hansard, 7 May 2010, p. 60. 

[24]      Mr Will Delaat, Chairman, Medicines Australia, Committee Hansard, 7 May 2010, p. 2. 

[25]      Pharmaceutical Society of Australia, Submission 17, p. 2. 

[26]      DoHA, Answers to questions on notice, 7 May 2010 (received 15 June 2010). 

[27]      DoHA, Answers to questions on notice, 7 May 2010 (received 15 June 2010).

[28]      Ms Toni Riley, National Councillor, The Pharmacy Guild of Australia, Committee Hansard, 7 May 2010, p. 38. 

[29]      Ms Toni Riley, National Councillor, The Pharmacy Guild of Australia, Committee Hansard, 7 May 2010, p. 40. 

[30]      See Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 7 May 2010, p. 6 & Ms Carol Bennett, Executive Director, CHF, Committee Hansard, 7 May 2010, p. 60. 

[31]      Medicines Australia, Submission 29, p. 14. 

[32]      National Health Act 1953, s. 84AG(3).

[33]      DoHA, Submission 27, p. 10. 

[34]      National Health Act 1953, s. 84AG(3).

[35]      Professor Markus Siebel, Council Member and Member of Therapeutics Committee, ANZBMS, Committee Hansard, 7 May 2010, p. 25. 

[36]      Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 7 May 2010, pp 8-9. 

[37]      DoHA, Submission 27, p. 14. 

[38]      DoHA, Answers to questions on notice, 7 May 2010 (received 15 June 2010). 

[39]      Professor Lloyd Sansom, Chair, Pharmaceutical Benefits Advisory Committee (PBAC), Committee Hansard, 7 May 2010, pp 75-76. 

[40]      Mr Will Delaat, Chairman, Medicines Australia, Committee Hansard, 7 May 2010, p. 2.  

[41]      Medicines Australia, Submission 29, pp 12-13. 

[42]      Professor Lloyd Sansom, Chair, PBAC, Committee Hansard, 7 May 2010, p. 75. 

CHAPTER 3 - EXEMPTION FROM PAYMENT OF THERAPEUTIC GROUP PREMIUMS

[1]        Department of Health and Ageing (DoHA), Submission 27, p. 15. 

[2]        DoHA, Submission 27, p. 15. 

[3]        Mr David Learmonth, Deputy Secretary, DoHA, Committee Hansard, 7 May 2010, p. 93. 

[4]        DoHA, Submission 27, p. 16. 

[5]        DoHA, Submission 27, p. 16. 

[6]        Professor John Eisman AO, Submission 6, p. 1.  See also Associate Professor Stephen Oakley, Committee Hansard, 7 May 2010, p. 67 & Dr Gabor Major, Committee Hansard, 7 May 2010, p. 70. 

[7]        Professor John Eisman AO, Submission 6, p. 1. See also Associate Professor Geoff Littlejohn, Submission 7, p. 1 & Dr David Kandiah, Submission 5, p. 1. 

[8]        Dr Gabor Major AC, Committee Hansard, 7 May 2010, p. 71.

[9]        Associate Professor Stephen Oakley & Dr Charles Inderjeeth, Member, Australian and New Zealand Society for Geriatric Medicine, Committee Hansard, 7 May 2010, pp 71 & 72. 

[10]      DoHA, Answers to questions on notice, 7 May 2010 (received 15 June 2010). 

CHAPTER 4 - CABINET CONSIDERATION THRESHOLD

[1]        Department of Health and Ageing (DoHA), Submission 27, p. 20. 

[2]        Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 7 May 2010, p. 11. 

[3]        Dr Brendan Shaw, Chief Executive, Medicines Australia, Committee Hansard, 7 May 2010, p. 11. 

[4]        Mr Will Delaat, Chairman, Medicines Australia, Committee Hansard, 7 May 2010, p. 3. 

[5]        Ms Carol Bennett, Executive Director, Consumers Health Forum of Australia (CHF), Committee Hansard, 7 May 2010, p. 61.

[6]        Productivity Commission, Annual Review of Regulatory Burdens: Manufacturing and Distributive Trades, September 2008, p. 80. 

CHAPTER 5 - OTHER ISSUES RAISED DURING THE INQUIRY

[1]        Generic Medicines Industry Association (GMiA), Submission 16, p. 14. 

[2]        GMiA, Submission 16, p. 13.

[3]        GMiA, Submission 16, p. 3. 

[4]        GMiA, Submission 16, p. 4. 

[5]        GMiA, Submission 16, p. 14. 

[6]        GMiA, Submission 16, p. 4.

[7]        GMiA, Submission 16, p. 4. 

[8]        GMiA, Submission 16, p. 5.

[9]        GMiA, Submission 16, p. 4. 

[10]      GMiA, Submission 16, p. 5. 

[11]      GMiA, Submission 16, p. 5. 

[12]      Pharmaceutical Society of Australia (PSA), Submission 17, p. 3. 

[13]      PSA, Submission 17, p. 3. 

[14]      PSA, Submission 17, p. 3. 

[15]      PSA, Submission 17, p. 4. 

[16]      PSA, Submission 17, pp 4-5. 

[17]      PSA, Submission 17, p. 6.

[18]      PSA, Submission 17, p. 7.

[19]      PSA, Submission 17, p. 7.

[20]      PSA, Submission 17, p. 7.

[21]      PSA, Submission 17, p. 7.